Medicare Enrolled
Dr. Michelle El-Hajjaoui, DO
Medical Oncology · West Covina, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. El-Hajjaoui from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. El-Hajjaoui?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. El-Hajjaoui
Dr. Michelle El-Hajjaoui is a medical oncology specialist in West Covina, CA, with 10 years of NPI registration. Based on federal Medicare data, Dr. El-Hajjaoui performed 34,022 Medicare services across 929 unique beneficiaries.
Between the years covered by Open Payments, Dr. El-Hajjaoui received a total of $3,888 from 37 pharmaceutical and/or device companies across 144 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. El-Hajjaoui is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 10 years in practice
▲ Top 13% volume in CA
$3,888 industry payments
Medicare Practice Summary
Medicare Utilization ↗34,022
Medicare services
Top 13% in CA for medical oncology
929
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,402 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
18,750 | $1 | $4 |
| Anti-nausea injection (aprepitant) | 7,670 | $1 | $6 |
| Denosumab injection (Prolia/Xgeva) | 2,700 | $18 | $83 |
| Anti-nausea injection (ondansetron/Zofran) | 1,552 | $0 | $0 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,134 | $0 | $0 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
359 | $99 | $433 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
336 | $83 | $374 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
220 | $14 | $93 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
157 | $76 | $341 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
148 | $119 | $606 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
122 | $12 | $81 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
121 | $110 | $481 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
121 | $64 | $285 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
98 | $109 | $471 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
74 | $26 | $147 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
72 | $1 | $5 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
58 | $59 | $295 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
56 | $25 | $134 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
50 | $59 | $269 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
42 | $1 | $4 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
33 | $25 | $109 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
33 | $1 | $20 |
| Advance care planning consultation, first 30 min A session focused on discussing and documenting future healthcare preferences and goals. This service covers the initial 30 minutes of the planning discussion. |
24 | $70 | $306 |
| Initial hospital admission, low complexity Initial hospital inpatient or observation care for a new patient involving straightforward or low-level medical decision making, with at least 40 minutes total time on the date of the encounter. |
19 | $69 | $301 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
18 | $149 | $672 |
| New patient office visit, complex (60-74 min) | 16 | $177 | $821 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
15 | $31 | $134 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
13 | $141 | $633 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
11 | $97 | $422 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
56.1% high complexity
40.9% medium
3.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$3,888
Total received (2018-2024)
Avg $555/year across 7 years
Bottom 47% in CA for medical oncology
37
Companies
144
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,317 (85.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$572 (14.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$793
2023
$38
2022
$392
2021
$1,445
2020
$620
2019
$492
2018
$108
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$201
AstraZeneca Pharmaceuticals LP
$104
Boston Scientific Corporation
$54
Merck Sharp & Dohme LLC
$45
Aveo Pharmaceuticals, Inc.
$36
Gilead Sciences, Inc.
$33
Janssen Biotech, Inc.
$30
SOBI, INC
$30
Daiichi Sankyo Inc.
$30
Tempus AI, Inc
$30
Takeda Pharmaceuticals U.S.A., Inc.
$29
Celgene Corporation
$28
ADC Therapeutics America, Inc.
$26
ImmunoGen, Inc.
$26
Lilly USA, LLC
$23
Eisai Inc.
$21
GENZYME CORPORATION
$18
E.R. Squibb & Sons, L.L.C.
$15
Amgen Inc.
$15
Top 3 companies account for 45.4% of 2024 payments
All-time payments by company (2018-2024) ›
Celgene Corporation
$473
Novartis Pharmaceuticals Corporation
$434
Incyte Corporation
$391
Lilly USA, LLC
$342
Merck Sharp & Dohme Corporation
$283
AbbVie Inc.
$143
GlaxoSmithKline, LLC.
$137
Seagen Inc.
$129
Blueprint Medicines Corporation
$129
AstraZeneca Pharmaceuticals LP
$128
Eisai Inc.
$127
Amgen Inc.
$115
Merck Sharp & Dohme LLC
$107
Janssen Biotech, Inc.
$104
Daiichi Sankyo Inc.
$73
PFIZER INC.
$73
Rigel Pharmaceuticals, Inc.
$69
GENZYME CORPORATION
$69
Gilead Sciences, Inc.
$63
JAZZ PHARMACEUTICALS INC.
$54
Boston Scientific Corporation
$54
Aveo Pharmaceuticals, Inc.
$36
TerSera Therapeutics LLC
$34
SOBI, INC
$30
Tempus AI, Inc
$30
Takeda Pharmaceuticals U.S.A., Inc.
$29
Adaptive Biotechnologies Corporation
$27
ADC Therapeutics America, Inc.
$26
ImmunoGen, Inc.
$26
Global Blood Therapeutics, Inc.
$25
Novocure Inc.
$23
Astellas Pharma US Inc
$21
SANOFI-AVENTIS U.S. LLC
$21
Clovis Oncology, Inc.
$18
Exelixis Inc.
$17
E.R. Squibb & Sons, L.L.C.
$15
Amarin Pharma Inc.
$13
Top 3 companies account for 33.4% of all-time payments
Associated products mentioned in payments ›
BRAFTOVI · Blincyto · CABLIVI · CALQUENCE · CARVYKTI · Cabometyx · DARZALEX · ELAHERE · ENHERTU · Enhertu · FOTIVDA · Fabhalta · GAVRETO · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · INREBIC · Inrebic · JAKAFI · KEYTRUDA · KISQALI · LUTATHERA · Lenvima · MEKINIST · OXBRYTA · Optune · PADCEV · PEMAZYRE · PIQRAY · Pomalyst · REBLOZYL · Revlimid · Rubraca · SARCLISA · SCEMBLIX · TABRECTA · TUKYSA · Tavalisse · TheraSphere Y90 Glass Microspheres 10 GBq · Truvada · VENCLEXTA · VERZENIO · VONJO · Vascepa · XTANDI · Xtandi · ZEJULA · ZEPZELCA · ZOLADEX · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (85%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Medical oncologists within 10 mi
75
Per 100K population
0.8
County median income
$87,760
Nearest hospital
KAISER FOUNDATION HOSPITAL - BALDWIN PARK
2.8 mi
2.8 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. El-Hajjaoui is a mixed practice specialist, with above-average Medicare volume (top 13% in CA), with low-engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. El-Hajjaoui experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. El-Hajjaoui performed 18,750 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. El-Hajjaoui receive payments from pharmaceutical companies?
Yes. Dr. El-Hajjaoui received a total of $3,888 from 37 companies across 144 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. El-Hajjaoui's costs compare to other medical oncologists in West Covina?
Dr. El-Hajjaoui's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. El-Hajjaoui) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in West Covina
Browse medical oncologists in West Covina ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in CA
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in CA
Which CA medical oncologists receive the most from drug and device companies.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology